^
Association details:
| Biomarker: | KMT2C mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
Published date:
06/06/2022
Excerpt:
Analysis of seven ICB-treated NSCLC cohorts revealed that mutations of three chromatin remodeling-related genes, including KMT2C, BCOR and KDM5C, were significantly associated with ICB response, and combined mutations of these three genes further enhance this association. NSCLC patients with KMT2C/BCOR/KDM5C mutations had comparable clinical outcomes to TMB-high patients in terms of objective response rate, durable clinical benefit and overall survival.
DOI:
https://doi.org/10.3390/cancers14112816
Source:
Title:
1639 - Correlation of KMT2C/D loss-of-function mutations with PD-L1 expression and response to immune checkpoint inhibitors in solid tumors
Published date:
03/10/2021
Excerpt:
We classified the patients into two groups: KMT2C/D LOF (any truncating mutation) and non-LOF….Furthermore, the median OS was also higher in the LOF group compared with the non-LOF group in NSCLC (undefined vs 12 months, P = 0.05)….Furthermore, KMT2C/D LOF mutations were also associated with better response to ICIs in colorectal cancer and NSCLC...
